Zoetis Inc. $ZTS Stock Holdings Cut by HighTower Advisors LLC

HighTower Advisors LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 452,685 shares of the company’s stock after selling 14,661 shares during the quarter. HighTower Advisors LLC owned 0.10% of Zoetis worth $66,238,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Halbert Hargrove Global Advisors LLC raised its position in Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares in the last quarter. NewSquare Capital LLC grew its stake in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the last quarter. Financial Consulate Inc. acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $39,000. SJS Investment Consulting Inc. raised its holdings in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC acquired a new stake in Zoetis during the third quarter valued at approximately $42,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Bank of America raised their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday. KeyCorp assumed coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Morgan Stanley set a $160.00 target price on Zoetis in a report on Thursday, December 18th. UBS Group set a $136.00 target price on Zoetis in a research report on Thursday, January 29th. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research report on Wednesday, December 3rd. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Stock Performance

Shares of ZTS stock opened at $126.64 on Tuesday. The company has a market capitalization of $53.46 billion, a price-to-earnings ratio of 21.04, a P/E/G ratio of 2.12 and a beta of 0.96. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock’s fifty day simple moving average is $124.59 and its 200-day simple moving average is $135.21.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same period last year, the company posted $1.40 EPS. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.